ERBB2 and prostate adenocarcinoma: Although the only approved indications for ERBB2 (encoding for HER2) inhibitors are BRCA and STAD24,25, we found a substantial fraction of other tumors—including 18% of MB, 16% of PRAD, and 15% of HCC—which overexpressed ERBB2.